{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:47:18Z","timestamp":1791244038399,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.ymgme.2006.09.010","type":"journal-article","created":{"date-parts":[[2006,11,21]],"date-time":"2006-11-21T17:16:31Z","timestamp":1164129391000},"page":"49-57","source":"Crossref","is-referenced-by-count":82,"title":["Chemical chaperones improve transport and enhance stability of mutant \u03b1-glucosidases in glycogen storage disease type II"],"prefix":"10.1016","volume":"90","author":[{"given":"Toshika","family":"Okumiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian A.","family":"Kroos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Van","family":"Vliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ans T.","family":"Van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold J.J.","family":"Reuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2006.09.010_bib1","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3389","article-title":"Glycogen storage disease II: acid \u03b1-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.ymgme.2006.09.010_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/humu.10286","article-title":"Twenty-two novel mutations in the lysosomal \u03b1-glucosidase gene (GAA) underscore the genotype\u2013phenotype correlation in glycogen storage disease type II","volume":"23","author":"Hermans","year":"2004","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2006.09.010_bib3","doi-asserted-by":"crossref","first-page":"8336","DOI":"10.1016\/S0021-9258(17)39477-2","article-title":"Defects in synthesis, phosphorylation, and maturation of acid \u03b1-glucosidase in glycogenosis type II","volume":"260","author":"Reuser","year":"1985","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2006.09.010_bib4","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1172\/JCI113008","article-title":"Clinical diversity in glycogenosis type II. Biosynthesis and in situ localization of acid \u03b1-glucosidase in mutant fibroblasts","volume":"79","author":"Reuser","year":"1987","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2006.09.010_bib5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ymgme.2003.11.011","article-title":"Glycogenosis type II: identification and expression of three novel mutations in the acid \u03b1-glucosidase gene causing the infantile form of the disease","volume":"81","author":"Montalvo","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2006.09.010_bib6","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2014macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2006.09.010_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-galactosidase A\u2014replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2006.09.010_bib8","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2006.09.010_bib9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2006.09.010_bib10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human \u03b1-l-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2006.09.010_bib11","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1542\/peds.2004-1023","article-title":"Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase","volume":"115","author":"Harmatz","year":"2005","journal-title":"Pediatrics"},{"issue":"Suppl. 91","key":"10.1016\/j.ymgme.2006.09.010_bib12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1651-2227.2002.tb03118.x","article-title":"Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report","author":"Muenzer","year":"2002","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2006.09.010_bib13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(00)02533-2","article-title":"Recombinant human \u03b1-glucosidase from rabbit milk in Pompe patients","volume":"356","author":"Van den Hout","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2006.09.010_bib14","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ana.20019","article-title":"Enzyme replacement therapy in late-onset Pompe\u2019s disease: a three-year follow-up","volume":"55","author":"Winkel","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2006.09.010_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1055\/s-2005-837543","article-title":"Enzyme replacement therapy in classical infantile Pompe disease: results of a ten-month follow-up study","volume":"36","author":"Klinge","year":"2005","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.ymgme.2006.09.010_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","article-title":"Chinese hamster ovary cell-derived recombinant human acid \u03b1-glucosidase in infantile-onset Pompe disease","volume":"149","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2006.09.010_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.febslet.2005.11.053","article-title":"Common antigenicity for two glycosidases","volume":"580","author":"Kakavanos","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ymgme.2006.09.010_bib18","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1006\/bbrc.1993.2659","article-title":"Characterization of a mutant \u03b1-galactosidase gene product for the late-onset cardiac form of Fabry disease","volume":"197","author":"Ishii","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymgme.2006.09.010_bib19","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1006\/bbrc.1995.2416","article-title":"Galactose stabilizes various missense mutants of \u03b1-galactosidase in Fabry disease","volume":"214","author":"Okumiya","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymgme.2006.09.010_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJM200107053450104","article-title":"Improvement in cardiac function in the cardiac variant of Fabry\u2019s disease with galactose-infusion therapy","volume":"345","author":"Frustaci","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2006.09.010_bib21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal \u03b1-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymgme.2006.09.010_bib22","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1046\/j.1432-1327.2000.01457.x","article-title":"In vitro inhibition and intracellular enhancement of lysosomal \u03b1-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives","volume":"267","author":"Asano","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ymgme.2006.09.010_bib23","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","article-title":"Chemical chaperones increase the cellular activity of N370S \u03b2-glucosidase: a therapeutic strategy for Gaucher disease","volume":"99","author":"Sawkar","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2006.09.010_bib24","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.chembiol.2005.09.007","article-title":"Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles","volume":"12","author":"Sawkar","year":"2005","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ymgme.2006.09.010_bib25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bcmd.2005.05.007","article-title":"Miglustat (NB-DNJ) works as a chaperone for mutated acid \u03b2-glucosidase in cells transfected with several Gaucher disease mutations","volume":"35","author":"Alfonso","year":"2005","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2006.09.010_bib26","doi-asserted-by":"crossref","first-page":"15912","DOI":"10.1073\/pnas.2536657100","article-title":"Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis","volume":"100","author":"Matsuda","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2006.09.010_bib27","doi-asserted-by":"crossref","first-page":"13478","DOI":"10.1074\/jbc.M308523200","article-title":"Pharmacological enhancement of \u03b2-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff patients","volume":"279","author":"Tropak","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2006.09.010_bib28","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1432-1033.1995.903_a.x","article-title":"Isolation and characterization of a recombinant, precursor form of lysosomal acid \u03b1-glucosidase","volume":"234","author":"Fuller","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ymgme.2006.09.010_bib29","first-page":"132","article-title":"Biochemical, immunological, and cell genetic studies in glycogenosis type II","volume":"30","author":"Reuser","year":"1978","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2006.09.010_bib30","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1093\/hmg\/3.12.2213","article-title":"The effect of a single base pair deletion (delta T525) and a C1634T missense mutation (pro545leu) on the expression of lysosomal \u03b1-glucosidase in patients with glycogen storage disease type II","volume":"3","author":"Hermans","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2006.09.010_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/(SICI)1098-1004(1997)9:1<17::AID-HUMU3>3.0.CO;2-M","article-title":"Two extremes of the clinical spectrum of glycogen storage disease type II in one family: a matter of genotype","volume":"9","author":"Kroos","year":"1997","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2006.09.010_bib32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0960-8966(00)00142-5","article-title":"Frequent mutations in Japanese patients with acid maltase deficiency","volume":"10","author":"Tsujino","year":"2000","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2006.09.010_bib33","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1042\/bj2890687","article-title":"The conservative substitution Asp-645\u2192Glu in lysosomal \u03b1-glucosidase affects transport and phosphorylation of the enzyme in an adult patient with glycogen-storage disease type II","volume":"289","author":"Hermans","year":"1993","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgme.2006.09.010_bib34","doi-asserted-by":"crossref","first-page":"13507","DOI":"10.1016\/S0021-9258(18)92727-4","article-title":"Human lysosomal \u03b1-glucosidase. Characterization of the catalytic site","volume":"266","author":"Hermans","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2006.09.010_bib35","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/BF01003850","article-title":"Immunocytochemistry of lysosomal hydrolases and their precursor forms in normal and mutant human cells","volume":"16","author":"Van Dongen","year":"1984","journal-title":"Histochem. J."},{"key":"10.1016\/j.ymgme.2006.09.010_bib36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/BF00295526","article-title":"Cotransfer of syntenic human genes into mouse cells using isolated metaphase chromosomes or cellular DNA","volume":"69","author":"de Jonge","year":"1985","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymgme.2006.09.010_bib37","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0092-8674(89)90685-5","article-title":"Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: evidence for membrane cycling from Golgi to ER","volume":"56","author":"Lippincott-Schwartz","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.ymgme.2006.09.010_bib38","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/nature02261","article-title":"Protein folding and misfolding","volume":"426","author":"Dobson","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2006.09.010_bib39","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0165-6147(03)00158-5","article-title":"A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity","volume":"24","author":"Fan","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ymgme.2006.09.010_bib40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000199188","article-title":"Effect of 1-desoxynojirimycin derivatives on small intestinal disaccharidase activities and on active transport in vitro","volume":"31","author":"Lembcke","year":"1985","journal-title":"Digestion"},{"key":"10.1016\/j.ymgme.2006.09.010_bib41","doi-asserted-by":"crossref","first-page":"93R","DOI":"10.1093\/glycob\/cwg090","article-title":"Glycosidase inhibitors: update and perspectives on practical use","volume":"13","author":"Asano","year":"2003","journal-title":"Glycobiology"},{"key":"10.1016\/j.ymgme.2006.09.010_bib42","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1042\/BJ20031822","article-title":"Cellular effects of deoxynojirimycin analogues: uptake, retention and inhibition of glycosphingolipid biosynthesis","volume":"381","author":"Mellor","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgme.2006.09.010_bib43","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1042\/BJ20031824","article-title":"Cellular effects of deoxynojirimycin analogues: inhibition of N-linked oligosaccharide processing and generation of free glucosylated oligosaccharides","volume":"381","author":"Mellor","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgme.2006.09.010_bib44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0092-8674(00)80724-2","article-title":"Brefeldin A: the advantage of being uncompetitive","volume":"97","author":"Chardin","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.ymgme.2006.09.010_bib45","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1002\/mus.880181414","article-title":"Glycogenosis type II (acid maltase deficiency)","volume":"3","author":"Reuser","year":"1995","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2006.09.010_bib46","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher\u2019s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2006.09.010_bib47","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1042\/bj20030348","article-title":"Membrane disruption and cytotoxicity of hydrophobic N-alkylated imino sugars is independent of the inhibition of protein and lipid glycosylation","volume":"374","author":"Mellor","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgme.2006.09.010_bib48","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.febslet.2006.03.010","article-title":"Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the \u03b1-glucosidase inhibitor miglustat","volume":"580","author":"Norez","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ymgme.2006.09.010_bib49","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S0021-9258(18)54189-2","article-title":"N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1\/V2 region of gp120","volume":"268","author":"Karlsson","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2006.09.010_bib50","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0006-2952(99)00384-6","article-title":"N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo","volume":"59","author":"Andersson","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ymgme.2006.09.010_bib51","doi-asserted-by":"crossref","first-page":"17173","DOI":"10.1073\/pnas.262586099","article-title":"Reversible infertility in male mice after oral administration of alkylated imino sugars: a nonhormonal approach to male contraception","volume":"99","author":"van der Spoel","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2006.09.010_bib52","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/humrep\/dei463","article-title":"Long-term non-hormonal male contraception in mice using N-butyldeoxynojirimycin","volume":"21","author":"Walden","year":"2006","journal-title":"Hum. Reprod."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719206003003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719206003003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T23:00:54Z","timestamp":1628118054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719206003003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S1096719206003003"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2006.09.010","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}